Streetbeat News

Regulatory

COIN

Coinbase Inc. (NASDAQ:COIN) has expanded its Global Advisory Council by adding former mayors Antonio Villaraigosa and Keisha Bottoms to leverage their political and policy-making expertise. This move aims to advance Coinbase's mission of promoting economic freedom worldwide, with a focus on bridging the gap between policymakers and the underbanked sectors of the American populace. The appointments are seen as crucial for guiding Coinbase in strategic decisions impacting global economic policies, especially in the context of increasing attention on the regulatory landscape for digital assets.

Portfolio Pulse from Murtuza Merchant

May 06, 2024 | 12:14 pm

X

The European Commission has approved the acquisition of sole control of United States Steel Corporation (X) by Nippon Steel Corporation. This approval is a significant step in the merger process, indicating regulatory clearance from the European Union.

Portfolio Pulse from Benzinga Newsdesk

May 06, 2024 | 12:14 pm

COIN

Six Coinbase customers have filed a class action lawsuit against Coinbase Global, Inc. (NASDAQ:COIN), accusing it of selling unregistered securities and violating state and federal securities laws. The lawsuit, filed in the Northern District of California, also names CEO Brian Armstrong and several subsidiaries as defendants. The plaintiffs allege Coinbase misled customers about its regulatory compliance, lacking necessary broker-dealer registrations.

Portfolio Pulse from Murtuza Merchant

May 06, 2024 | 12:08 pm

BCAB

BioAtla announced that the FDA has cleared its Investigational New Drug (IND) application for BA3361, a new drug candidate. This clearance allows BioAtla to proceed with clinical trials in the United States, marking a significant step forward in the development of BA3361.

Portfolio Pulse from Benzinga Newsdesk

May 06, 2024 | 12:07 pm

VYNE

VYNE Therapeutics has received FDA clearance for its Investigational New Drug (IND) application for VYN202. This marks a significant milestone for the company, allowing it to proceed with clinical trials for VYN202, potentially impacting its future revenue and growth prospects.

Portfolio Pulse from Benzinga Newsdesk

May 06, 2024 | 12:04 pm

MASI

Masimo (NASDAQ:MASI), a leader in monitoring technologies, announced FDA clearance for its Stork baby monitoring system for healthy babies aged 0-18 months, available without prescription.

Portfolio Pulse from Benzinga Newsdesk

May 06, 2024 | 12:04 pm

ALLR

Allarity Therapeutics has surpassed Nasdaq's minimum equity requirement and has requested a voluntary withdrawal of its Form S-1. This move indicates the company's improved financial position and its decision to not proceed with the previously planned public offering.

Portfolio Pulse from Benzinga Newsdesk

May 06, 2024 | 12:02 pm

LYRA

Lyra Therapeutics announced that its Phase 3 ENLIGHTEN 1 trial for LYR-210, aimed at treating chronic rhinosinusitis, did not meet its primary endpoint. Despite some improvements in symptoms, the results were not statistically significant compared to sham control. The company plans to evaluate the full dataset and determine its next steps, including making near-term business operation changes and workforce reductions to preserve cash. The ENLIGHTEN 1 trial is ongoing, with 52-week extension phase results expected in Q4 2024, and the ENLIGHTEN 2 trial is also in progress.

Portfolio Pulse from Benzinga Newsdesk

May 06, 2024 | 12:01 pm

OMH

Ohmyhome's stock price has increased following the announcement that the company received a Nasdaq deficiency notice.

Portfolio Pulse from Benzinga Newsdesk

May 06, 2024 | 11:44 am

OMH

Ohmyhome Limited received a Nasdaq deficiency notice due to its share price falling below the $1.00 minimum requirement for 30 consecutive days. The company has 180 days, until October 28, 2024, to regain compliance. If unsuccessful, it may receive an extension or face delisting. Ohmyhome intends to explore options to address the issue.

Portfolio Pulse from Benzinga Newsdesk

May 06, 2024 | 11:41 am